Literature DB >> 23605504

Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery.

John Varlotto1, Achilles Fakiris, John Flickinger, Laura Medford-Davis, Adam Liss, Julia Shelkey, Chandra Belani, Jill DeLuca, Abram Recht, Neelabh Maheshwari, Robert Barriger, Nengliang Yao, Malcolm DeCamp.   

Abstract

BACKGROUND: Stereotactic body radiotherapy (SBRT) is an alternative to surgery for clinical stage I non-small cell lung cancer (NSCLC), but comparing its effectiveness is difficult because of differences in patient selection and staging.
METHODS: Two databases were combined which contained patients treated from 1999 to 2008 by lobectomy (LR, n = 132), sublobar resection (SLR, n = 48), and SBRT (n = 137) after negative staging. Univariate and multivariate analysis were performed for survival (OS), total recurrence control (TRC comprises local-regional and distant control), and locoregional control (LRC) in our entire population. A matched-pair analysis was also performed that compared surgery and SBRT results. Median follow-up for the entire study population was 25.8 months.
RESULTS: On univariate analysis, OS was significantly worse with SBRT and also correlated with histology, the Charlson comorbidity index, tumor size, and aspirin use; TRC correlated only with histology; and no variable significantly correlated with LRC. OS was significantly poorer for SBRT in the matched-pair analysis than for patients treated with surgery, but TRC and LRC were not significantly different between these groups. Multivariate analyses including propensity score as a covariate (controlling for all factors affecting treatment selection) found that OS correlated only with Charlson comorbidity index, and TRC correlated only with tumor grade. LRC correlated only with tumor size with or without propensity score correction.
CONCLUSIONS: This retrospective study has demonstrated similar OS, LRC, and TRC with SBRT or surgery after controlling for prognostic and patient selection factors. Randomized clinical trials are needed to better compare the effectiveness of these treatments.
© 2013 American Cancer Society.

Entities:  

Keywords:  lobectomy; lung cancer; matched-pair; radiosurgery; stereotactic ablative body radiation; stereotactic body radiotherapy; sublobar resection

Mesh:

Year:  2013        PMID: 23605504     DOI: 10.1002/cncr.28100

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  32 in total

1.  Improving lung cancer outcomes by improving the quality of surgical care.

Authors:  Raymond U Osarogiagbon; Thomas A D'Amico
Journal:  Transl Lung Cancer Res       Date:  2015-08

2.  Stereotactic ablative radiotherapy (SABR) in operable early stage non-small cell lung cancer (NSCLC) patients: challenge to claim being undisputed gold standard.

Authors:  Deniz Yalman; Ugur Selek
Journal:  Ann Transl Med       Date:  2015-07

Review 3.  New techniques for assessing response after hypofractionated radiotherapy for lung cancer.

Authors:  Sarah A Mattonen; Kitty Huang; Aaron D Ward; Suresh Senan; David A Palma
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

4.  eComment. Is surgery still worthwhile as compared to stereotactic ablative radiotherapy or CyberKnife in high-risk surgical patients with Stage I non-small-cell-lung cancer?

Authors:  Paolo Scanagatta
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-11

5.  Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in Canada.

Authors:  Alexander V Louie; George B Rodrigues; David A Palma; Suresh Senan
Journal:  Oncologist       Date:  2014-06-20

6.  Surgery versus SABR for early stage non-small cell lung cancer: the moving target of equipoise.

Authors:  Houda Bahig; Hanbo Chen; Alexander V Louie
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

Review 7.  Stereotactic body radiotherapy: current strategies and future development.

Authors:  Maverick W K Tsang
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

Review 8.  Treatment of early stage non-small cell lung cancer: surgery or stereotactic ablative radiotherapy?

Authors:  Esengül Koçak Uzel; Ufuk Abacıoğlu
Journal:  Balkan Med J       Date:  2015-01-01       Impact factor: 2.021

9.  Surgery versus stereotactic body radiotherapy for clinical stage I non-small-cell lung cancer: propensity score-matching analysis including the ratio of ground glass nodules.

Authors:  N Tomita; K Okuda; S Osaga; A Miyakawa; R Nakanishi; Y Shibamoto
Journal:  Clin Transl Oncol       Date:  2020-07-23       Impact factor: 3.405

10.  A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer.

Authors:  Christopher Cao; Daniel Wang; Caroline Chung; David Tian; Andreas Rimner; James Huang; David R Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2018-09-15       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.